Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention
Objectives: To investigate the potential association between early tirofiban treatment and N-terminal pro-B-type natriuretic peptide (NT-proBNP) level after primary percutaneous coronary intervention (PCI). Background: Whether the use of adjunctive early glycoprotein IIb/IIIa inhibitors (GPIs) thera...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2019
|
| In: |
Catheterization and cardiovascular interventions
Year: 2018, Volume: 93, Issue: 5, Pages: E293-E297 |
| ISSN: | 1522-726X |
| DOI: | 10.1002/ccd.28043 |
| Online Access: | Verlag, Pay-per-use, Volltext: https://doi.org/10.1002/ccd.28043 Verlag, Pay-per-use: https://onlinelibrary.wiley.com/doi/abs/10.1002/ccd.28043 
|
| Author Notes: | Enrico Fabris, Jan Paul Ottervanger, Renicus S. Hermanides, Jurrien M. ten Berg, Gianfranco Sinagra, Petra C. Koopmans, Evangelos Giannitsis, Christian Hamm, Arnoud W.J. van ‘t Hof |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1681918986 | ||
| 003 | DE-627 | ||
| 005 | 20220817024657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191114r20192018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ccd.28043 |2 doi | |
| 035 | |a (DE-627)1681918986 | ||
| 035 | |a (DE-599)KXP1681918986 | ||
| 035 | |a (OCoLC)1341250577 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fabris, Enrico |e VerfasserIn |0 (DE-588)1171143729 |0 (DE-627)1040384072 |0 (DE-576)513604669 |4 aut | |
| 245 | 1 | 0 | |a Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention |c Enrico Fabris, Jan Paul Ottervanger, Renicus S. Hermanides, Jurrien M. ten Berg, Gianfranco Sinagra, Petra C. Koopmans, Evangelos Giannitsis, Christian Hamm, Arnoud W.J. van ‘t Hof |
| 264 | 1 | |c 2019 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.11.2019 | ||
| 500 | |a First published: 26 December 2018 | ||
| 520 | |a Objectives: To investigate the potential association between early tirofiban treatment and N-terminal pro-B-type natriuretic peptide (NT-proBNP) level after primary percutaneous coronary intervention (PCI). Background: Whether the use of adjunctive early glycoprotein IIb/IIIa inhibitors (GPIs) therapy, may affect the level of NT-proBNP after primary PCI is poorly studied. Methods: Nine hundred and eighty four ST-elevation myocardial infarction (STEMI) patients undergoing primary PCI were randomized to either pre-hospital tirofiban administration or placebo. NT-proBNP levels were evaluated on admission before angiography (baseline) and 18-96 hr after PCI. Results: There were 918 (93.3%) patients with NT-proBNP values available at baseline and 865 (87.9%) post-PCI. Post-PCI NT-proBNP level dichotomized with median value as cut-off (968.8 pg/mL, IQR 430.9-1970.0) was significantly lower in patients treated with early tirofiban as compared to placebo (45.5% vs. 54.2% P = 0.011). At multivariate logistic regression analysis, independent predictors of post-PCI NT-proBNP level above the median were: NT-proBNP baseline level (OR 5.19; 95% CI, 2.92-9.25, P < 0.001), Killip class>I (OR 4.07; 95% CI 1.24-13.36, P = 0.021), anterior infarct location (OR 2.61; 95% CI 1.84-3.70, P < 0.001), age (years) (OR 1.04; 95% CI 1.03-1.06, P < 0.001), male gender (OR 0.38; 95% CI 0.26-0.57, P < 0.001), prior PCI (OR 0.49; 95% CI 0.27-0.90, P = 0.021) and tirofiban administration (OR 0.71; 95% CI 0.51-0.99; P = 0.045). Conclusions: In a large cohort of STEMI patients, pre-hospital tirofiban administration was independently associate with a lower risk of high NT-proBNP level after primary PCI, supporting the potential benefit of early antithrombotic treatment administration in STEMI patients. The trial is registered under No. ISRCTN06195297. | ||
| 534 | |c 2018 | ||
| 650 | 4 | |a glycoprotein IIb/IIIa inhibitors | |
| 650 | 4 | |a NT-proBNP | |
| 650 | 4 | |a STEMI | |
| 650 | 4 | |a tirofiban | |
| 700 | 1 | |a Giannitsis, Evangelos |e VerfasserIn |0 (DE-588)113336241 |0 (DE-627)577184091 |0 (DE-576)289759579 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Catheterization and cardiovascular interventions |d New York, NY : Wiley Interscience, 1999 |g 93(2019), 5, Seite E293-E297 |h Online-Ressource |w (DE-627)320413004 |w (DE-600)2001555-0 |w (DE-576)091014794 |x 1522-726X |7 nnas |a Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention |
| 773 | 1 | 8 | |g volume:93 |g year:2019 |g number:5 |g pages:E293-E297 |g extent:5 |a Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention |
| 856 | 4 | 0 | |u https://doi.org/10.1002/ccd.28043 |x Verlag |x Resolving-System |z Pay-per-use |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ccd.28043 |x Verlag |z Pay-per-use |
| 951 | |a AR | ||
| 992 | |a 20191114 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 113336241 |a Giannitsis, Evangelos |m 113336241:Giannitsis, Evangelos |d 910000 |d 910100 |e 910000PG113336241 |e 910100PG113336241 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 999 | |a KXP-PPN1681918986 |e 3540329129 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Enrico Fabris, Jan Paul Ottervanger, Renicus S. Hermanides, Jurrien M. ten Berg, Gianfranco Sinagra, Petra C. Koopmans, Evangelos Giannitsis, Christian Hamm, Arnoud W.J. van ‘t Hof"]},"language":["eng"],"person":[{"family":"Fabris","role":"aut","given":"Enrico","display":"Fabris, Enrico"},{"display":"Giannitsis, Evangelos","given":"Evangelos","role":"aut","family":"Giannitsis"}],"recId":"1681918986","note":["Gesehen am 14.11.2019","First published: 26 December 2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention","title_sort":"Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention"}],"id":{"doi":["10.1002/ccd.28043"],"eki":["1681918986"]},"physDesc":[{"extent":"5 S."}],"relHost":[{"pubHistory":["46.1999 -"],"note":["Gesehen am 21.01.04"],"language":["eng"],"part":{"text":"93(2019), 5, Seite E293-E297","issue":"5","extent":"5","pages":"E293-E297","year":"2019","volume":"93"},"disp":"Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary interventionCatheterization and cardiovascular interventions","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"320413004","origin":[{"dateIssuedDisp":"1999-","publisher":"Wiley Interscience","publisherPlace":"New York, NY","dateIssuedKey":"1999"}],"title":[{"subtitle":"official journal of the Society for Cardiac Angiography & Interventions","title":"Catheterization and cardiovascular interventions","title_sort":"Catheterization and cardiovascular interventions"}],"id":{"issn":["1522-726X"],"eki":["320413004"],"zdb":["2001555-0"],"doi":["10.1002/(ISSN)1522-726X"]},"physDesc":[{"extent":"Online-Ressource"}]}],"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}]} | ||
| SRT | |a FABRISENRIEFFECTOFEA2019 | ||